Morikawa, T.; Naiki, T.; Sugiyama, Y.; Naiki-Ito, A.; Nagai, T.; Etani, T.; Iida, K.; Isobe, T.; Noda, Y.; Shimizu, N.;
et al. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers 2024, 16, 1725.
https://doi.org/10.3390/cancers16091725
AMA Style
Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N,
et al. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers. 2024; 16(9):1725.
https://doi.org/10.3390/cancers16091725
Chicago/Turabian Style
Morikawa, Toshiharu, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu,
and et al. 2024. "C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study" Cancers 16, no. 9: 1725.
https://doi.org/10.3390/cancers16091725
APA Style
Morikawa, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Iida, K., Isobe, T., Noda, Y., Shimizu, N., Aoki, M., Gonda, M., Banno, R., Kubota, H., Ando, R., Umemoto, Y., Kawai, N., & Yasui, T.
(2024). C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers, 16(9), 1725.
https://doi.org/10.3390/cancers16091725